**Question:** What is the global prevalence of classic phenylketonuria based on Neonatal Screening Program Data?

**Finding:** The overall worldwide prevalence of the disease is 6.002 per 100,000 neonates. The highest prevalence (38.13) was reported in Turkey, while the lowest (0.3) in Thailand.

**Meaning:** This difference in the prevalence may be due to differences in the number of consanguineous marriages among the different regions, phenylalanine cutoff points, and sample sizes.
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Introduction
============

Genetic and congenital abnormalities are the most important causes of death and malformation in the first month of life \[[@b1-kjp-2019-00465]\]. Phenylketonuria (PKU) is an inborn error of amino acid metabolism caused by phenylalanine hydroxylase gene mutations \[[@b2-kjp-2019-00465],[@b3-kjp-2019-00465]\]. PKU patients experience an irreversible decrease in intelligence quotient scores, suppressed verbal function, impaired attention, and underdeveloped motor control skills \[[@b4-kjp-2019-00465],[@b5-kjp-2019-00465]\].

The early diagnosis of PKU before the end of the first month of life is critical to controlling hyperphenylalaninemia \[[@b4-kjp-2019-00465],[@b6-kjp-2019-00465]\]. Children with PKU seem normal during the first days of life; however, nervous system damage progresses gradually and becomes apparent over several months \[[@b7-kjp-2019-00465]\]. The early detection of PKU in the asymptomatic period and treatment with a phenylalanine restricted diet is warranted to ensure normal development \[[@b8-kjp-2019-00465]-[@b12-kjp-2019-00465]\]. Therefore, neonatal screening as a fundamental public health intervention started in the mid-20th century \[[@b4-kjp-2019-00465],[@b12-kjp-2019-00465],[@b13-kjp-2019-00465]\].

Since PKU has autosomal recessive inheritance, consanguineous marriage is an important risk factor \[[@b1-kjp-2019-00465],[@b4-kjp-2019-00465]\]; thus, countries with a high prevalence of consanguineous marriages have high disease prevalence \[[@b6-kjp-2019-00465],[@b14-kjp-2019-00465]\]. PKU varies among ethnic groups, races, and geographic regions. For example, In Japan, the incidence is reportedly 1:108,822 \[[@b15-kjp-2019-00465]\]. Turkey, with an incidence of 1:6,000, and Iran, with an incidence of 1:4,698, are among the countries with the highest PKU incidences \[[@b16-kjp-2019-00465],[@b17-kjp-2019-00465]\].

Despite numerous studies conducted in various countries on PKU prevalence using screening programs, no study has systematically compared the prevalence of PKU across regions and countries or sources of heterogeneity. To address this gap, this systematic review and meta-analysis aimed to investigate the worldwide prevalence of PKU. Moreover, many countries have acknowledged the benefits of newborn screening programs for PKU. Moreover, newborn screening programs have enabled the rapid and large-scale testing of many children with good quality control.

Methods
=======

This systematic review adhered to the guidelines of the Joanna Briggs Institute Reviewers' Manual 2014, Systematic Review of Prevalence Data \[[@b18-kjp-2019-00465]\]. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2009 flow diagram was used to guide the study identification and selection process \[[@b19-kjp-2019-00465]\].

1. Search method
----------------

The PubMed, Web of Sciences, Sciences Direct, ProQuest, and Scopus databases were searched on Oct 28, 2018, without publication date restrictions. The search strategy carefully captured all potentially eligible records of PKU prevalence. A combination of medical subject headings (MeSH) and similar text words in English was used. Google Scholar was searched, as were the reference lists of the reviewed articles to identify additional relevant articles.

The key MeSH terms were as follows: (Infants OR Newborns OR Neonate) AND (Phenylketonuria OR Hyperphenylalaninemia, Non-Phenylketonuric OR BH4 Deficiency OR Tetrahydrobiopterin Deficiency OR Phenylketonuria II OR DHPR Deficiency OR Dihydropteridine Reductase Deficiency OR Atypical PKU) AND (Incidence OR Prevalence) and Screening. No time limitation was considered for the database search.

2. Inclusion criteria
---------------------

All original articles that directly reported PKU prevalence based on newborn screening of populations were included. A newborn, infant, or neonate is a child younger than 28 days of age; in this review, the sampling period was limited to the first 28 days of life. All studies were included if they used a laboratory screening test for disease detection.

Reviews, comments, and letters were excluded. Moreover, studies that reported the prevalence in a selective neonatal population (congenital diseases, intellectual disability), those that included children older than 28 days, and those that indirectly estimated prevalence according to consanguinity or the incidence of another genetic disease were excluded. In some cases, studies were conducted of the same PKU prevalence in one country using different dates; in such cases, the more recent study (which also included the data from the older study) was included and the older study was omitted. Moreover, studies that detected PKU based on clinical manifestations in neonates or neural tube defects in fetuses were excluded.

3. Data collection
------------------

The title, abstract, and keywords of every identified article were carefully scanned and relevant articles were selected by title or abstract review.

4. Data extraction and management
---------------------------------

Two reviewers (HSH. and FZ) independently extracted the patient characteristics, study characteristics, screening test used, and incidence from the reviewed studies using a data extraction form. Any disagreements between the 2 researchers were solved by consultation of another reviewer or a clinical adviser. Abstracts not published as full texts were not included in the study. To avoid data entry errors, all results were double-entered into a data extraction form. The included studies used different units such as mmol/L, μmol/dL, and mg/dL to report phenylalanine level. However, in this study, to increase comparability, all units were converted to mg/dL. In addition, to ensure more accurate comparisons, PKU prevalence was calculated as percentage and rate per 100,000 screened neonates.

5. Assessment of methodological quality
---------------------------------------

Article quality was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for studies that reported prevalence data. Each article was evaluated according to the following methodological criteria: appropriate sample, adequate sample size, valid methodology, valid measure to detect the disease, and an appropriate statistical analysis.

6. Risk of bias
---------------

Risk of bias was assessed using the risk of bias tool for studies measuring disease prevalence designed and developed by Hoy et al. \[[@b20-kjp-2019-00465]\] Based on this 10-point checklist, studies were assessed for internal and external validity and grouped as having high, moderate, or low bias risk. Studies with a score of 9--10 were considered at having low risk of bias; 6--8, as having moderate risk; and less than 6, as having high risk. Those studies with a high risk of bias were excluded from the meta-analysis.

7. Data analysis
----------------

The data were analyzed using Stata ver. 12 (StataCorp LP., College Station, TX, USA). In a meta-analysis, pooled prevalence was estimated based on World Health Organization (WHO) regions and reported as per 100,000 neonates/population with 95% confidence interval (CI).

The degrees of heterogeneity among the included studies are expressed by the *I*^2^ heterogeneity statistic, and the random effects model was used to estimate the pooled prevalence in subgroups. A forest plot was used to display the meta-analysis results.

The mixed model test considered WHO regions as a random intercept. In this test, phenylalanine levels were modeled as independent variables, while prevalence was considered a dependent variable.

Furthermore, a meta-regression analysis was performed to investigate the impact of variables such as WHO region, phenylalanine cutoff point, study period, national or governmental screening program, and participant age on the *I*^2^ and pooled prevalence.

Results
=======

1. Study selection
------------------

After a comprehensive search, 1,228 relevant articles were identified, 608 duplicates were removed. The relevance of the remaining 1,346 studies was evaluated based on the titles/abstracts alone; of them, 99 studies were subjected to fulltext review, which eliminated another 46 studies according to the inclusion and exclusion criteria. Finally, 53 studies with 119,152,905 participants were included in the present systematic review; of them, 46 were included in the meta-analysis ([Fig. 1](#f2-kjp-2019-00465){ref-type="fig"}).

2. Risk of bias
---------------

In the bias assessment, 7 studies scored below 6 (high risk) and were excluded from the meta-analysis; thus, the pooled global prevalence was estimated without them \[[@b11-kjp-2019-00465]-[@b13-kjp-2019-00465],[@b21-kjp-2019-00465]-[@b24-kjp-2019-00465]\]. Moreover, 33 of the studies scored 6--8 (moderate risk) \[[@b1-kjp-2019-00465],[@b9-kjp-2019-00465],[@b16-kjp-2019-00465],[@b17-kjp-2019-00465],[@b25-kjp-2019-00465]-[@b53-kjp-2019-00465]\], while the other 13 studies had low risk \[[@b2-kjp-2019-00465],[@b10-kjp-2019-00465],[@b54-kjp-2019-00465]-[@b64-kjp-2019-00465]\].

3. Study characteristics
------------------------

In this section, the systematic review results are presented based on different characteristics, including region, test, and participant characteristics.

4. Region characteristics
-------------------------

The included studies (1964--2017) are presented in [Table 1](#t1-kjp-2019-00465){ref-type="table"}. The longest study, conducted in France, examined 35 years of screening data from 1966 to 2001 \[[@b56-kjp-2019-00465]\]. The largest screening population was in China (35,795,550 newborns for 30 years from the start of the screening project); the largest number of cases was detected (3,082 patients) in this study \[[@b60-kjp-2019-00465]\]. However, the smallest population belonged to a study conducted in Iraq in 2015, and only 8,255 newborns were screened \[[@b13-kjp-2019-00465]\].

5. Participants' characteristics
--------------------------------

Sampling age at screening was below 5 days in 30 studies \[[@b1-kjp-2019-00465],[@b2-kjp-2019-00465],[@b9-kjp-2019-00465],[@b10-kjp-2019-00465],[@b16-kjp-2019-00465],[@b17-kjp-2019-00465],[@b21-kjp-2019-00465],[@b23-kjp-2019-00465],[@b27-kjp-2019-00465],[@b29-kjp-2019-00465],[@b31-kjp-2019-00465]-[@b33-kjp-2019-00465],[@b35-kjp-2019-00465],[@b39-kjp-2019-00465],[@b41-kjp-2019-00465],[@b43-kjp-2019-00465]-[@b46-kjp-2019-00465],[@b48-kjp-2019-00465],[@b50-kjp-2019-00465]-[@b53-kjp-2019-00465],[@b56-kjp-2019-00465]-[@b58-kjp-2019-00465],[@b60-kjp-2019-00465],[@b61-kjp-2019-00465]\], 5--10 days in 15 studies \[[@b13-kjp-2019-00465],[@b22-kjp-2019-00465],[@b28-kjp-2019-00465],[@b30-kjp-2019-00465],[@b34-kjp-2019-00465],[@b37-kjp-2019-00465],[@b42-kjp-2019-00465],[@b47-kjp-2019-00465],[@b49-kjp-2019-00465],[@b54-kjp-2019-00465],[@b55-kjp-2019-00465],[@b59-kjp-2019-00465],[@b62-kjp-2019-00465],[@b63-kjp-2019-00465],[@b65-kjp-2019-00465]\], and over 10 days in 3 studies \[[@b25-kjp-2019-00465],[@b26-kjp-2019-00465],[@b38-kjp-2019-00465]\]. Five studies did not report newborn age at screening \[[@b11-kjp-2019-00465],[@b12-kjp-2019-00465],[@b24-kjp-2019-00465],[@b36-kjp-2019-00465],[@b64-kjp-2019-00465]\].

The neonatal participation rate was reported in 23 studies \[[@b1-kjp-2019-00465],[@b10-kjp-2019-00465],[@b11-kjp-2019-00465],[@b24-kjp-2019-00465],[@b27-kjp-2019-00465],[@b28-kjp-2019-00465],[@b33-kjp-2019-00465],[@b34-kjp-2019-00465],[@b44-kjp-2019-00465],[@b46-kjp-2019-00465]-[@b48-kjp-2019-00465],[@b50-kjp-2019-00465],[@b53-kjp-2019-00465]-[@b60-kjp-2019-00465],[@b62-kjp-2019-00465],[@b63-kjp-2019-00465]\]; of them, it was above 90% in 7 studies \[[@b11-kjp-2019-00465],[@b27-kjp-2019-00465],[@b34-kjp-2019-00465],[@b46-kjp-2019-00465],[@b47-kjp-2019-00465],[@b57-kjp-2019-00465],[@b59-kjp-2019-00465]\]. The participation rate increased with the progression of the screening process in 8 studies \[[@b1-kjp-2019-00465],[@b24-kjp-2019-00465],[@b27-kjp-2019-00465],[@b36-kjp-2019-00465],[@b56-kjp-2019-00465],[@b58-kjp-2019-00465],[@b60-kjp-2019-00465],[@b62-kjp-2019-00465]\].

Moreover, 6 studies reported the percentage of consanguineous marriages among the parents of newborns with PKU \[[@b1-kjp-2019-00465],[@b13-kjp-2019-00465],[@b16-kjp-2019-00465],[@b17-kjp-2019-00465],[@b21-kjp-2019-00465],[@b50-kjp-2019-00465]\]. The percentage of consanguineous marriages varied from 45% in Turkey \[[@b16-kjp-2019-00465]\] to 100% in Iraq \[[@b13-kjp-2019-00465]\].

6. Test characteristics
-----------------------

In the included studies, 2 stages were used to diagnose infants with classical PKU.

7. Screening tests
------------------

A total of 19 studies reported the number of positive cases in the first stage of screening. The phenylalanine cutoff point for separating positive cases and referrals for diagnostic testing ranged from 1.65 mg/dL to 20 mg/dL. The highest recall rate in the first stage of screening was 378 per 100,000 neonates in a study conducted in Russia \[[@b35-kjp-2019-00465]\].

8. Diagnostic tests
-------------------

In the diagnostic stage, the phenylalanine cutoff point for diagnosing classic PKU patients ranged from 1.65 mg/dL to 20 mg/dL. Moreover, 22 studies selected 20 mg/dL as the positive cutoff point and 5 studies did not report a cutoff point \[[@b2-kjp-2019-00465],[@b9-kjp-2019-00465],[@b16-kjp-2019-00465],[@b22-kjp-2019-00465],[@b25-kjp-2019-00465],[@b26-kjp-2019-00465],[@b31-kjp-2019-00465]-[@b36-kjp-2019-00465],[@b43-kjp-2019-00465],[@b44-kjp-2019-00465],[@b46-kjp-2019-00465],[@b51-kjp-2019-00465],[@b55-kjp-2019-00465],[@b57-kjp-2019-00465],[@b58-kjp-2019-00465],[@b62-kjp-2019-00465]-[@b64-kjp-2019-00465]\].

9. Pooled global prevalence of classic PKU
------------------------------------------

Among the included studies, the highest prevalence was found in Turkey (38.13), followed by Iran, with a prevalence of 21.28 per 100,000 neonates \[[@b17-kjp-2019-00465],[@b31-kjp-2019-00465]\], while the lowest prevalence was reported in studies conducted in Thailand (0.3) and Taiwan (0.44) \[[@b42-kjp-2019-00465],[@b46-kjp-2019-00465] [@b47-kjp-2019-00465],[@b64-kjp-2019-00465]\].

A subgroup estimation of the polled prevalence showed that the pooled prevalence of classic PKU in the included studies was 6.002 (95% CI, 5.07--6.93). The highest prevalence was seen in Eastern Mediterranean (9.83; 95% CI, 6.18--13.48), Europe (8.11; 95% CI, 6.54--9.69), Pan America (5.32; 95% CI, 4.47--6.07), Western Pacific (2.94; 95% CI, 0.91--4.97), and Southeast Asia (0.32; 95% CI, 0.19--0.45) per 100,000 neonates ([Fig. 2](#f3-kjp-2019-00465){ref-type="fig"}).

10. Statistical analysis
------------------------

According to the results of mixed model, cutoff point selection had no effect on prevalence. The p value obtained from the likelihood ratio test in the mixed model test suggested that the random intercept model was appropriate. Moreover, based on the intraclass coefficient, 29% of the PKU prevalence changes in different countries were justified by consideration of the WHO regions ([Table 2](#t2-kjp-2019-00465){ref-type="table"}).

A meta-regression test was used to assess the effect of year, phenylalanine cutoff point, region, neonate age at screening, and screening level (national or regional) on heterogeneity.

In the naïve model without any variables, *I*^2^ was 99%. Several models with different variables were created in which *I*^2^ ranged was 97%--99%, and the input of different variables did not decrease the heterogeneity.

Among the variables included in the model, only some WHO regions were significant. In the meta-regression model, the European region was selected as a reference. In the Eastern Mediterranean region, the prevalence was 1.01 greater than that in the European region, but the difference was not significant. The pooled prevalence of the different regions is reported in [Table 3](#t3-kjp-2019-00465){ref-type="table"}.

According to *I*^2^ by region and overall, the studies had high heterogeneity ([Table 4](#t4-kjp-2019-00465){ref-type="table"}).

Discussion
==========

This systematic review aimed to investigate the worldwide prevalence of PKU and provided a general picture of its status. The results of this study demonstrate that the worldwide prevalence of the disease is 0.3--38.13 per 100,000 newborns. However, the meta-analysis revealed that the *I*^2^ index, which indicates heterogeneity, was reported for all regions except Southeast Asia (91.8%) and Pan America (99.7%), indicating high heterogeneity among countries and regions.

The uni- and multivariate models in the meta-regression showed that phenylalanine level, geographical area, neonate age at screening, screening level (national or regional), after the control for year of study, did not change heterogeneity.

However, the differences in prevalence can be attributed to 2 factors: (1) variability of the factors affecting disease worldwide; and (2) differences in the methods used in the studies.

PKU is a c0ngenital genetic disease; thus, factors such as culture, customs, consanguineous marriage, and genetics are expected to affect its incidence but among included studies only 6 studies in Iran, Iraq, Turkey, and the United Arab Emirates \[[@b1-kjp-2019-00465],[@b13-kjp-2019-00465], [@b16-kjp-2019-00465],[@b17-kjp-2019-00465],[@b21-kjp-2019-00465],[@b50-kjp-2019-00465]\] reported consanguineous marriages among parents of children with PKU.

Therefore, a lack of information about the prevalence of PKU in many countries in which consanguineous marriage is prevalent and a lack of reporting consanguineous marriage status in parents of children with PKU in many studies prevented us from controlling the effect of this variable on prevalence.

The next important determinant of prevalence is study performance; factors such as diagnostic tests, cutoff point, and sample size can affect the pooled prevalence in prevalence studies.

However, in the mixed model test, there was no significant relationship between cutoff point and disease prevalence, which might have been due to the effect of the confounding variables. However, the difference was noticeable when the cutoff point differed in the same population and within the same country. For example, in 3 studies conducted during 2000--2008 in Fars province (Iran), a different cutoff point was found. Moreover, Senemar chose a phenylalanine level of ≤4 mg/dL to define classical PKU and reported a prevalence of 21.28 \[[@b17-kjp-2019-00465]\]. Habib et al. \[[@b45-kjp-2019-00465]\] considered a phenylalanine ≤10 mg/dL cutoff value and reported a prevalence of 15.97. Furthermore, in the study of Karamifar et al. \[[@b9-kjp-2019-00465]\], phenylalanine levels above 20 mg/dL were considered positive and a prevalence of 10.39 was reported.

Sample size is the other factor involved in the difference in prevalence among studies. In a meta-analysis, the pooled prevalence is estimated according to the sample size, and larger studies have greater impact on prevalence. Thus, although studies conducted in the Eastern Mediterranean region reported higher prevalence than those in the Western Pacific region, since most studies in the latter had a larger sample size and the weighted sample size in that region was 24.83%, higher than that in the Eastern Mediterranean region (16.2%), the pooled prevalence in studies conducted in the Eastern Mediterranean region was close to that of the Western Pacific region.

Although this study addressed an important concern in genetic diseases, its findings may not be highly accurate, as there were many sources of heterogeneity in the reviewed studies that could have affected their pooled prevalence. Moreover, some heterogeneous sources might not have been identified. However, the standardization of study methods can partly solve this problem.

One of the limitations of this study was the failure to report consanguineous marriage in parents of newborns with PKU. Thus, it was not possible to answer the following question:

Is the difference in PKU prevalence among different countries due to differences in the number of consanguineous marriages?

Thus, we suggest that consanguineous marriages be recorded and reported in screening programs designed to identify patients with PKU and other congenital metabolic diseases.

In conclusion, all relevant studies conducted in 1964--2017 were included in this review. The highest PKU prevalence was observed in Turkey (38.13), while the lowest was seen in Thailand (0.3). Among the WHO regions, the highest prevalence belonged to Eastern Mediterranean Regional Office, while the lowest was in Southeast Asia. This difference in the prevalence may be due to differences in the number of consanguineous marriages among the different regions, phenylalanine cutoff points, and sample sizes.
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###### 

Description of studies included in the study

  ID   Study                                                Study location             Popuiation size   Study period   Age taking a biood sampie   Screening test/cutoff level (mg/dL)                                                            No. of cases in screening test (incidence per 100,000)   Diagnostic test/cutoff level for classic PKU (mg/dL)                                        No. of classic PKU cases (incidence per 100,000)   Consanguinity   Neonatal participation rate        Rist of bias Score   Remarks                                                                                                    WHO regions
  ---- ---------------------------------------------------- -------------------------- ----------------- -------------- --------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------- -------------------------------------------------- --------------- ---------------------------------- -------------------- ---------------------------------------------------------------------------------------------------------- -----------------------
  1    MacCready, \[[@b25-kjp-2019-00465]\] 1964            USA/Massachusetts          134,580           1962--1964     28 Days                     Guthrie/≥4                                                                                     NA                                                       Guthrie/≥4                                                                                  14 (10.4)                                          NA              NA                                 7                                                                                                                               Pan American
  2    Peterson, \[[@b26-kjp-2019-00465]\] 1968             USA/Caiifornia             311,953           1966           30 Days                     Guthrie and Fluorometric/20                                                                    NA                                                       Guthrie and Fluorometric/≥20                                                                16 (5.12)                                          NA              NA                                 6                                                                                                                               Pan American
  3    Fox, \[[@b27-kjp-2019-00465]\] 1971                  Canada/Manitoba            85,868            1966--1970     4-5 Days                    Guthrie test/20                                                                                NA                                                       Guthrie test/≥20                                                                            5 (5.82)                                           NA              95.7%                              8                                                                                                                               Pan American
  4    Alm, \[[@b54-kjp-2019-00465]\] 1981                  Sweden                     1,362,497         1965--1979     4-6 Days                    Ion exchange chromatography/4.12                                                               312 (22.89)                                              Ion exchange chromatography/≥4.12                                                           43 (3.15)                                          NA              86%                                9                    The phenylalanine cut point reported 0.25 mmol/L, this is equal to 4.12 mg/dL                              Europe
  5    Antonozzi, \[[@b28-kjp-2019-00465]\] 1982            Itaiy/3 regions            220,000           1974--1981     Median of 7.6 days          Ion exchange chromatography/1.65                                                               211 (95.9)                                               Ion exchange chromatography/≥1.65                                                           23 (10.45)                                         NA              42%                                6                    The phenyl alanine cut point reported 100 μmol/dL, this is equal to 1.65 mg/dL                             Europe
  6    Farhud, \[[@b22-kjp-2019-00465]\] 1982               Iran/Tehran                8,633             1982           4-8 Days                    Guthrie/20                                                                                     NA                                                       Guthrie/≥ 20                                                                                1 (11.58)                                          NA              NA                                 5                                                                                                                               Eastern Mediterranean
  7    Liu, \[[@b29-kjp-2019-00465]\] 1986                  china/11 province          198,320           1982--1985     1-3 Days                    Guthrie/4                                                                                      225 (113.4)                                              Guthrie/≥15                                                                                 9 (4.53)                                           NA              NA                                 8                    Reports overall incidence 1:16500 but the incidence is 1:22035                                             Western Pacific
  8    Mathias, \[[@b30-kjp-2019-00465]\] 1986              West Germany               940,369           1969--1984     5-7 Days                    Guthrie/15                                                                                     170 (18.07)                                              Ion exchange chromatography/≥15                                                             94 (10)                                            NA              NA                                 8                                                                                                                               Europe
  9    Özalp, \[[@b31-kjp-2019-00465]\] 1986                Turkey/Ankara              20,979            1983--1985     \>24 Hr                     Guthrie/4                                                                                      NA                                                       Fluorometric/≥20                                                                            8 (38.13)                                          NA              NA                                 8                                                                                                                               Europe
  10   Aoki, \[[@b55-kjp-2019-00465]\] 1988                 Japan                      12,168,645        1977--1985     5-7 Days                    Guthrie/20                                                                                     NA                                                       Guthrie/≥20                                                                                 102 (0.83)                                         NA              87%                                10                                                                                                                              Western Pacific
  11   Missiou-Tsagaraki, \[[@b32-kjp-2019-00465]\] 1988    Greece                     1,042,000         1974--1986     \>24 Hr                     Thin-layer chromatography/4                                                                    776 (74.47)                                              Thin-layer chromatography/≥20                                                               43 (4.12)                                          NA              NA                                 8                                                                                                                               Europe
  12   Chen, \[[@b33-kjp-2019-00465]\] 1989                 China/Shanghai             358,767           1981--1989     \>3 Days                    Guthrie/4                                                                                      72 (20.06)                                               Fluorometric/≥ 20                                                                           21 (5.85)                                          NA              33%                                6                                                                                                                               Western Pacific
  13   Smith, \[[@b34-kjp-2019-00465]\] 1991                United Kingdom             3,796,645         1984--1988     6-7 Days                    9 Laboratories Guthrie, 6 used fluorometric and 11 used thin layer or paper chromatography/4   NA                                                       9 Laboratories Guthrie, 6 used fluorometric and 11 used layer or paper chromatography/≥20   273 (7.19)                                                         100%                               8                    The phenylalanine cut point reported 240 μmol/dL, this is equal to 4 mg/dL                                 Europe
  14   Gerasimova, \[[@b35-kjp-2019-00465]\] 1992           Russia, Moscow             139,664           1990--1991     4-5 Days                    Fluorometric/3                                                                                 529 (378)                                                Fluorometric/≥20                                                                            21 (15.03)                                         NA              NA                                 7                    The phenylalanine cut point reported 180 μmol/dL, this is equal to 3 mg/dL                                 Europe
  15   Cabalska, \[[@b36-kjp-2019-00465]\] 1993             Poland                     2,861,504         1965--1990     NA                          Guthrie/4                                                                                      NA                                                       Guthrie/≥20                                                                                 368 (12.86)                                        NA              40%--100%                          8                    They just presented data from the National Research Institute for Mother and Child                         Europe
  16   Fernandez-Iglesias, \[[@b37-kjp-2019-00465]\] 1995   Spain/Principado           75,488            1982--1993     5-8 Days                    Thin-layer chromatography/4                                                                    NA                                                       High performance liquid chromatography/≥4                                                   5 (6.62)                                           NA              NA                                 7                    The phenylalanine cut point reported 240 pmol/dL, this is equal to 4 mg/dL                                 Europe
  17   Hitzeroth, \[[@b23-kjp-2019-00465]\] 1995            South Africa/Pretoria      59,600            1979--1986     3-5 Days                    Thin-layer chromatography/4                                                                    NA                                                       Thin-layer chromatography/NA                                                                1 (1.67)                                           NA              NA                                 5                                                                                                                               Africa
  18   Özalp, \[[@b16-kjp-2019-00465]\] 1995                Turkey                     576,122           1987--1994     \>24 Hr                     Fluorometric/20                                                                                NA                                                       Fluorometric/≥ 20                                                                           96 (16.66)                                         45%             NA                                 7                    The phenylalanine cut point reported 1,200 μmol/dL, this is equal to 20 mg/dL)                             Europe
  19   Kucinskas, \[[@b38-kjp-2019-00465]\] 1996            Uthuania                   907,168           1975--1993     21 Days                     Fluorometric/2.5                                                                               NA                                                       Fluorometric/≥ 2.5                                                                          85 (9.36)                                          NA              NA                                 8                    The phenylalanine cut point reported 150 pmol/dL, this is equal to 2.5 mg/dL                               Europe
  20   Ounap, \[[@b66-kjp-2019-00465]\] 1998                Estonia                    36,074            1993--1995     3-5 Days                    Fluorometric/3                                                                                 NA                                                       Fluorometric /≥3                                                                            6 (16.63)                                          NA              85%                                7                    The phenyl alanine cut point reported 180 pmol/dL, this is equal to 3 mg/dL                                Europe
  21   Abadie, \[[@b56-kjp-2019-00465]\] 2001               France                     21,500,000        1966--2001     3-5 Days                    Until 1990 (Guthrie) 1991--2001 (Fluorometric)/10                                              1,426 (6.63)                                             Until 1990 (Guthrie), 1991--2001 (Fluorometric)/≥10                                         1,164 (5.41)                                       NA              3%--65%                            9                    The phenylalanine cut point reported 600 pmol/dL, this is equal to 10 mg/dL                                Europe
  22   Zytkovicz, \[[@b39-kjp-2019-00465]\] 2001            England                    257,000           1999--2001     1-3 Days                    MS/MS/2.29                                                                                     92 (35.79)                                               MS/MS/≥2.29                                                                                 7 (2.72)                                           NA              NA                                 8                    The phenylalanine cut point reported 139 pmol/dL, this is equal to 2.29 mg/dL                              Europe
  23   Schulze, \[[@b40-kjp-2019-00465]\] 2002              Germany                    423,773           1994--1999     5 Days (1--10 days)         MS/MS/2.5                                                                                      NA                                                       MS/MS/≥10                                                                                   41 (9.67)                                          NA              NA                                 8                    The phenylalanine cut point reported 150 pmol/dL, this is equal to 2.5 mg/dl                               Europe
  24   Zaffanello, \[[@b57-kjp-2019-00465]\] 2002           Northeastern Italy         1,142,338         1978--1997     3-5 Days                    Guthrie/2                                                                                      NA                                                       High performance liquid chromatography/≥20                                                  25 (2.18)                                          NA              97%                                9                                                                                                                               Europe
  25   Capistrano-Estrada, \[[@b41-kjp-2019-00465]\] 2003   Philippines                189,720           1996--2001     \>24 Hr                     Guthrie/3.3                                                                                    75 (39.53)                                               Guthrie/≥3.3                                                                                3 (1.58)                                           NA              NA                                 6                    The phenylalanine cut point reported 200 pmol/dL, this is equal to 3.3 mg/dL                               Western Pacific
  26   Charoensiriwatana, \[[@b42-kjp-2019-00465]\] 2003    Thailand                   1,425,025         1992--2001     2-7 Days                    Guthrie/4                                                                                      321 (22.52)                                              Fluorometric/≥4                                                                             5 (0.35)                                           NA              NA                                 7                                                                                                                               South-East Asia
  27   Jiang, \[[@b43-kjp-2019-00465]\] 2003                China/Guangdong            461,805           NA             3 Days                      Guthrie and Fluorometric/2                                                                     NA                                                       Guthrie and Fluorometric/≥20                                                                6 (1.29)                                           NA              NA                                 7                    The phenylalanine cut point reported 120 pmol/dL, this is equal to 2 mg/dL                                 Western Pacific
  28   Yoon, \[[@b44-kjp-2019-00465]\] 2005                 South Korea                5,243,841         1996--2006     NA                          Guthrie and Fluorometric/4                                                                     NA                                                       High performance liquid chromatography/≥20                                                  16 (0.3)                                           NA              NA                                 8                                                                                                                               Western Pacific
  29   Pangkanon, \[[@b67-kjp-2019-00465]\] 2009            Thailand                   79,179            2001--2004     2-3 Days                    MS/MS/2.29                                                                                     NA                                                       MS/MS/≥20                                                                                   5 (6.31)                                           NA              5.40%                              9                    The phenylalanine cut point reported 139 pmol/dL, this is equal to 2.29 mg/dL                              South-East Asia
  30   Senemar, \[[@b17-kjp-2019-00465]\] 2009              Iran/Fars                  70,477            2000--2005     3 Days                      Fluorometric/4                                                                                 NA                                                       Fluorometric/≥4                                                                             15 (21.28)                                         86.60%          NA                                 7                                                                                                                               Eastern Mediterranean
  31   Cornejo, \[[@b58-kjp-2019-00465]\] 2010              Chile                      2,478,123         1992--2008     3.6 Mean                    Fluorometric/20                                                                                NA                                                       1998--2002 Fluorometric-2002--2008 MS/MS/≥20                                                131 (5.28)                                         NA              48-98%                             9                                                                                                                               Pan American
  32   Habib, \[[@b45-kjp-2019-00465]\] 2010                Iran/Fars                  175,235           2004--2007     3-5 Days                    Enzymatic colorimetric method/4                                                                30 (17.11)                                               High performance liquid chromatography/≥10                                                  28 (15.97)                                         NA              NA                                 8                                                                                                                               Eastern Mediterranean
  33   Karamifar, \[[@b9-kjp-2019-00465]\] 2010             Iran/Fars                  76,966            2007--2008     3-5 Days                    Enzymatic colorimetric method/2                                                                9 (11.69)                                                High performance liquid chromatography/≥20                                                  8 (10.39)                                          NA              NA                                 8                                                                                                                               Eastern Mediterranean
  34   Niu, \[[@b46-kjp-2019-00465]\] 2010                  Taiwan                     1,495,132         2000--2009     2-3 Days                    MS/MS/4                                                                                        NA                                                       MS/MS/≥20                                                                                   5 (0.33)                                           NA              \>99%                              8                    The phenylalanine cut point reported 240 pmol/dL, this is equal to 4 mg/dL                                 Western Pacific
  35   Vilarinho, \[[@b59-kjp-2019-00465]\] 2010            Portugal                   316,243           2004--2008     3-6 Days                    MS/MS/2.5                                                                                      NA                                                       MS/MS/≥6                                                                                    26 (8.22)                                          NA              99.80%                             9                    The phenylalanine cut point reported 150 pmol/dL, this is equal to 2.5 mg/dL                               Europe
  36   Sutivijit, \[[@b47-kjp-2019-00465]\] 2011            Thailand/Southern Region   1,118,676         2000--2009     \>2 Days                    Guthrie/4                                                                                      120 (10.72)                                              Fluorometric/≥4                                                                             5 (0.44)                                           NA              near 100%                          8                                                                                                                               South-East Asia
  37   Botler, \[[@b10-kjp-2019-00465]\] 2012               Brazil                     541,248           2005--2007     2-5 Days                    Fluorometric/4                                                                                 64 (11.82)                                               Thin layer amino acid chromatography≥10                                                     26 (4.8)                                           NA              71-80%                             9                                                                                                                               Pan American
  38   Shi, \[[@b60-kjp-2019-00465]\] 2012                  China                      35,795,550        1981--2011     2-3 Days                    Guthrie/2                                                                                      NA                                                       Fluorometric: ≥2 Guthrie: ≥4                                                                3,082 (8.6)                                        NA              3.86% in 2003 and 59.01% in 2009   9                    The phenylalanine cut point reported 120 pmol/dL, this is equal to 2 mg/dL                                 Western Pacific
  39   Yang, \[[@b61-kjp-2019-00465]\] 2012                 China/Zhejiang             3,791,538         1999--2010     3-5 Days                    Fluorescent ninhydrine method/2                                                                NA                                                       Fluorescent ninhydrine method/≥2                                                            143 (3.77)                                         NA              NA                                 9                    The phenylalanine cut point reported 120 pmol/dL, this is equal to 2 mg/dL                                 Western Pacific
  40   Dluholucký, \[[@b11-kjp-2019-00465]\] 2013           Slovakia                   927,524           1995--2012     NA                          Guthrie/NA                                                                                     NA                                                       Fluorometric (NA)                                                                           157 (16.92)                                        NA              98%                                5                                                                                                                               Europe
  41   Al Hosani, \[[@b62-kjp-2019-00465]\] 2014            United Arab Emirates       750,365           1995--2011     \>2 Days                    Time-resolved fluorescence/4                                                                   57 (7.59)                                                1995-2001 time-resolved fluorescence application 2011 MS/MS/≥20                             51 (6.79)                                          NA              1995-50%, 2010-95%                 10                                                                                                                              Eastern Mediterranean
  42   Dluholucký, \[[@b12-kjp-2019-00465]\] 2014           Slovakia                   82,892            2013--2014     NA                          MS/MS/NA                                                                                       NA                                                       MS/MS (NA)                                                                                  5 (6.03)                                           NA              NA                                 5                                                                                                                               Europe
  43   Ramalho, \[[@b63-kjp-2019-00465]\] 2014              Brazil/Sergipe             43,449            2007--2008     2-6 Days                    Enzymatic colorimetric method/ 5                                                               NA                                                       Enzymatic colorimetric method/≥20                                                           4 (9.2)                                            NA              78.93%                             9                                                                                                                               Pan American
  44   Hamawandi, \[[@b13-kjp-2019-00465]\] 2015            Iraq/Sulaimani             8,255             2013--2014     3-10 Days                   ELISA/4                                                                                        11 (133.25)                                              High performance liquid chromatography/≥4                                                   1 (12.11)                                          100%            NA                                 5                                                                                                                               Eastern Mediterranean
  45   Šmon, \[[@b2-kjp-2019-00465]\] 2015                  Slovenia                   385,831           1993--2012     3-5 Days                    Fluorometric/3.3                                                                               NA                                                       Fluorometric/≥20                                                                            38 (9.84)                                          NA              NA                                 9                    The phenylalanine cut point reported 0.2 mmol/l, this is equal to 3.3 mg/dL                                Europe
  46   Hassan, \[[@b49-kjp-2019-00465]\] 2016               Egypt                      25,276            2008           3-7 Days                    MS/MS/2.5                                                                                      NA                                                       MS/MS/≥1.69                                                                                 5 (19.78)                                          NA              NA                                 6                    The phenylalanine cut point reported 150 μmol/dL, this is equal to 2.5 mg/dL                               Eastern Mediterranean
  47   Zhong, \[[@b24-kjp-2019-00465]\] 2016                China                      13,187,196        2013           NA                          NA/NA                                                                                          NA                                                       NA                                                                                          1,123 (8.51)                                       NA              10%-85%                            4                                                                                                                               Western Pacific
  48   Al-Jasmi, \[[@b21-kjp-2019-00465]\] 2016             United Arab Emirates       136,049           2011--2014     3-5 Days                    MS/MS/NA                                                                                       NA                                                       MS/MS (NA)                                                                                  11 (8.08)                                          81%             NA                                 5                                                                                                                               Eastern Mediterranean
  49   Alkhazrajy, \[[@b48-kjp-2019-00465]\] 2016           Iraq/Baghdad               80,409            2014           3-5 Days                    MS/MS/2.5                                                                                      NA                                                       MS/MS/≥1.69                                                                                 6 (7.46)                                           NA              66%                                6                    Self-calculated Prevalence. Article did not report prevalence of PKU.                                      Eastern Mediterranean
  50   Saadatpour, \[[@b50-kjp-2019-00465]\] 2016           Iran/Hormogan              71,677            2014--2016     3-5 Days                    ELISA/2                                                                                        15 20.92)                                                High performance liquid chromatography≥4 mg/dL                                              3 (4.18)                                           66%             88%                                8                    Consanguinity Reported 53 % but from 3 positive case 2 had Consanguinity marriage and should correct 66%   Eastern Mediterranean
  51   Alfadhel, \[[@b52-kjp-2019-00465]\] 2017             Saudi Arabia               775,000           2005--2012     After 24 hr of birth        MS/MS/3                                                                                        NA                                                       MS/MS≥2.03                                                                                  53 (6.83)                                          NA              NA                                 7                                                                                                                               Eastern Mediterranean
  52   Abbaskhanian, \[[@b51-kjp-2019-00465]\] 2017         Iran/Mazandaran            407,244           2007--2015     3-5 Days                    ELISA/4                                                                                        465 (114.18)                                             High performance liquid chromatography\>20                                                  6 (1.47)                                           NA              NA                                 8                                                                                                                               Eastern Mediterranean
  53   Motamedi, \[[@b1-kjp-2019-00465]\] 2017              Iran/Lorestan              384,993           2006--2016     3-5 Days                    High performance liquid chromatography/4                                                       NA                                                       High performance liquid chromatography≥4                                                    74 (19.22)                                         82%             53.60%                             7                                                                                                                               Eastern Mediterranean

PKU, phenylketonuria; WHO, World Health Organization; MS/MS, tandem mass spectrometry; ELISA, enzyme-linked immunosorbent assay; NA, not announced.

###### 

Result of mixed model test

  Variable                     Coefficient   SE      *P* value   Estimate   95% CI
  ---------------------------- ------------- ------- ----------- ---------- --------------
  Cut-point level              -0.03         0.11    0.792                  
  Random-effect parameter                                                   
  WHO regions (var constant)                 12.07               15.61      3.43--71.08
  Var (residual)                             8.09                36.27      23.43--56.16

SE, standard error; CI, confidence interval; WHO, World Health Organization.

Intraclass correlation coefficient=0.29. Likelihood-ratio test=0.0019.

###### 

Result of meta-regression test

  WHO region              Coefficient   SE     *P* value   *I^2^*
  ----------------------- ------------- ------ ----------- --------
  Europe                  Reference                        98.69%
  Eastern Mediterranean   1.01          1.89   0.593       
  Pan American            -2.03         2.15   0.350       
  Western Pacific         -5.37         1.72   0.003       
  Southeast Asia          -7.97         2.54   0.003       

WHO, World Health Organization; SE, standard error.

###### 

Prevalence rate and heterogeneity in regions

  WHO region              *P* value   *I^2^*   Prevalence in 100 000 neonates (range)   Pooled prevalence in 100,000 neonates
  ----------------------- ----------- -------- ---------------------------------------- ---------------------------------------
  Pan American            0.49        0        4.8--10.4                                5.32
  Europe                  \<0.0001    95.1%    2.18--38.13                              8.12
  Western Pacific         \<0.0001    99.7%    0.3--8.6                                 2.94
  Southeast Asia          0.79        0        0.3--0.44                                0.32
  Eastern Mediterranean   \<0.0001    91.8%    1.47--21.28                              9.84
  Overall                 \<0.0001    99%      1.47--38.13                              6.002

WHO, World Health Organization.
